A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
|Videos|October 21, 2021
Evolving Fellowship Training in Multiple Sclerosis
Ahmed Obeidat, MD, PhD; Jeffrey Cohen, MD; and Erin Longbrake, MD, PhD discuss the evolution of fellowship training for multiple sclerosis specialists.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Jeffrey Cohen, MD
Director, Mellen Center for Multiple Sclerosis Treatment and Research; Director, Experimental Therapeutics Program, Cleveland Clinic - Erin Longbrake, MD, PhD
Assistant Professor of Neurology; Director, Fellowship Program, Multiple Sclerosis & Other Inflammatory Brain Disease, Yale School of Medicine
Key Learning Objectives
- Fellowship training paths in multiple sclerosis
- Subspecialty certification training in multiple sclerosis
- Practical advice for the clinical care of multiple sclerosis
- The future of clinician training for multiple sclerosis care
Advertisement
Related to this article
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.
One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.
The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
A newly published 10-year analysis of the OPERA I and II trials reported that starting ocrelizumab 2 years earlier was associated with less disability accrual in relapsing MS, with no new safety signals.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
2
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
3
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
4
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
5